-
Something wrong with this record ?
L-arginine in combination with sildenafil potentiates the attenuation of hypoxic pulmonary hypertension in rats
H. Al-Hiti, M. Chovanec, V. Melenovský, O. Vajnerová, A. Baňasová, J. Kautzner, J. Herget
Language English Country Czech Republic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT13358
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Arginine administration & dosage MeSH
- Hypoxia complications drug therapy physiopathology MeSH
- Drug Therapy, Combination MeSH
- Blood Pressure drug effects MeSH
- Rats MeSH
- Piperazines administration & dosage MeSH
- Hypertension, Pulmonary drug therapy etiology physiopathology MeSH
- Rats, Wistar MeSH
- Purines administration & dosage MeSH
- Sulfones administration & dosage MeSH
- Drug Synergism MeSH
- Vasodilator Agents administration & dosage MeSH
- Pulmonary Gas Exchange drug effects MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Chronic hypoxia induces an increased production of nitric oxide (NO) in pulmonary prealveolar arterioles. Bioavailability of the NO in the pulmonary vessels correlates with concentration of L-arginine as well as activity of phosphodiesterase-5 enzyme (PDE-5). We tested a hypothesis whether a combination of L-arginine and PDE-5 inhibitor sildenafil has an additive effect in reduction of the hypoxic pulmonary hypertension (HPH) in rats. Animals were exposed to chronic normobaric hypoxia for 3 weeks. In the AH group, rats were administered L-arginine during chronic hypoxic exposure. In the SH group, rats were administered sildenafil during chronic hypoxic exposure. In the SAH group, rats were treated by the combination of L-arginine as well as sildenafil during exposure to chronic hypoxia. Mean PAP, structural remodeling of peripheral pulmonary arterioles (%DL) and RV/LV+S ratio was significantly decreased in the SAH group compared to hypoxic controls even decreased compared to the AH and the SH groups in first two measured parameters. Plasmatic concentration of cGMP and NOx were significantly lower in the SAH group compared to hypoxic controls. We demonstrate that NO synthase substrate L-arginine and phosphodiesterase-5 inhibitor sildenafil administered in combination are more potent in attenuation of the HPH compared to a treatment by substances given alone.
Department of Cardiology Institute for Clinical and Experimental Medicine Prague
Department of Cardiology Na Homolce Hospital Prague
Department of Pathophysiology 2nd Medical School Charles University Prague Czech Republic
Department of Physiology 2nd Medical School Charles University Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14069004
- 003
- CZ-PrNML
- 005
- 20190920124849.0
- 007
- ta
- 008
- 140825s2013 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.932463 $2 doi
- 035 __
- $a (PubMed)23869884
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Al-Hiti, Hikmet, $d 1970- $7 xx0073834 $u Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic. milan.chovanec@lfmotol.cuni.cz; Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague
- 245 10
- $a L-arginine in combination with sildenafil potentiates the attenuation of hypoxic pulmonary hypertension in rats / $c H. Al-Hiti, M. Chovanec, V. Melenovský, O. Vajnerová, A. Baňasová, J. Kautzner, J. Herget
- 520 9_
- $a Chronic hypoxia induces an increased production of nitric oxide (NO) in pulmonary prealveolar arterioles. Bioavailability of the NO in the pulmonary vessels correlates with concentration of L-arginine as well as activity of phosphodiesterase-5 enzyme (PDE-5). We tested a hypothesis whether a combination of L-arginine and PDE-5 inhibitor sildenafil has an additive effect in reduction of the hypoxic pulmonary hypertension (HPH) in rats. Animals were exposed to chronic normobaric hypoxia for 3 weeks. In the AH group, rats were administered L-arginine during chronic hypoxic exposure. In the SH group, rats were administered sildenafil during chronic hypoxic exposure. In the SAH group, rats were treated by the combination of L-arginine as well as sildenafil during exposure to chronic hypoxia. Mean PAP, structural remodeling of peripheral pulmonary arterioles (%DL) and RV/LV+S ratio was significantly decreased in the SAH group compared to hypoxic controls even decreased compared to the AH and the SH groups in first two measured parameters. Plasmatic concentration of cGMP and NOx were significantly lower in the SAH group compared to hypoxic controls. We demonstrate that NO synthase substrate L-arginine and phosphodiesterase-5 inhibitor sildenafil administered in combination are more potent in attenuation of the HPH compared to a treatment by substances given alone.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a hypoxie $x komplikace $x farmakoterapie $x patofyziologie $7 D000860
- 650 _2
- $a arginin $x aplikace a dávkování $7 D001120
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a plicní hypertenze $x farmakoterapie $x etiologie $x patofyziologie $7 D006976
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a piperaziny $x aplikace a dávkování $7 D010879
- 650 _2
- $a výměna plynů v plicích $x účinky léků $7 D011659
- 650 _2
- $a puriny $x aplikace a dávkování $7 D011687
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a sulfony $x aplikace a dávkování $7 D013450
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vazodilatancia $x aplikace a dávkování $7 D014665
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chovanec, Milan $7 xx0104171 $u Department of Cardiology, Na Homolce Hospital, Prague; Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic
- 700 1_
- $a Melenovský, Vojtěch $7 xx0160847 $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague
- 700 1_
- $a Vajnerová, Olga $7 xx0036859 $u Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic
- 700 1_
- $a Baňasová, Alena, $d 1973- $7 xx0074189 $u Department of Pathophysiology, Second Medical School, Charles University, Prague, Czech Republic
- 700 1_
- $a Kautzner, Josef, $d 1957- $7 xx0037112 $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague
- 700 1_
- $a Herget, Jan, $d 1945-2019 $7 nlk19990073223 $u Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 62, č. 6 (2013), s. 589-595
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20140825 $b ABA008
- 991 __
- $a 20190920125241 $b ABA008
- 999 __
- $a ok $b bmc $g 1037342 $s 867847
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 62 $c 6 $d 589-595 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- GRA __
- $a NT13358 $p MZ0
- LZP __
- $b NLK118 $a Pubmed-20140825